Granted Patent
B2
US 12,590,160 · App. 17/814,704 · Granted Mar 31, 2026
Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of TL1A function
Inventors:
David Q. Shih (La Crescenta, CA); Stephan R. Targan (Santa Monica, CA); Dalin Li (Walnut, CA); Janine Bilsborough (Adelaide, AU)
Assignee:
CEDARS-SINAI MEDICAL CENTER
C07K16/2866A61K39/3955C07K16/241C07K16/2875C07K16/2878C12N15/1138G01N33/6869C07K16/24C07K2317/76C12Q1/6883C12Q2600/112C12Q2600/158G01N2333/7155G01N2800/065G01N2800/10
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
Claims (12)
1 . A method of reversing intestinal fibrosis in a subject having inflammatory bowel disease (IBD), comprising:
(a) assaying and detecting a high level of connective tissue growth factor (Ctgf) in a sample obtained from the subject with intestinal fibrosis, wherein the high level of Ctgf is high as compared to a level of Ctgf in a normal individual;
(b) administering to the subject in which the high level of Ctgf was detected in (a) a therapeutically effective dosage of one or more inhibitors of tumor necrosis factor-like cytokine 1A-death domain receptor 3 (TL1A)-(DR3) binding comprising a blocking TL1A antibody; and
(c) reducing the high level of Ctgf in the subject, thereby reversing the intestinal fibrosis in the subject, wherein reversing comprises reversal of the intestinal fibrosis to a level present in the subject prior to contracting the IBD.
2 . The method of claim 1 , wherein the intestinal fibrosis is colonic fibrosis.
3 . The method of claim 1 , wherein the Ctgf is RNA.
4 . The method of claim 1 , wherein reversing comprises a decrease in a number of fibroblasts and/or myofibroblasts in the subject.
5 . The method of claim 1 , wherein reversing comprises a decrease in a number of primary intestinal myofibroblasts in the subject.
6 . The method of claim 1 , wherein the IBD is Crohn's disease (CD).
7 . The method of claim 6 , wherein the CD is a severe form of the disease.
8 . The method of claim 1 , wherein the subject has strictures in a small intestine.
9 . The method of claim 1 , wherein the subject has intestinal fibrostenosis.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 23, 2022
From: SHIH, DAVID Q.; TARGAN, STEPHAN R.; LI, DALIN; BILSBOROUGH, JANINE
To: CEDARS-SINAI MEDICAL CENTER
Reel/Frame 061199/0333 →
Continuity (4)
Continuation
14779893
Provisional Application
61872020
· Aug 30, 2013
References Cited (112)
US 7708996B2
· Yu et al.
· 2010
[cited by applicant]
US 8017122B2
· Siadak et al.
· 2011
[cited by applicant]
US 8263743B2
· Smith et al.
· 2012
[cited by applicant]
US 9068003B2
· Siegel et al.
· 2015
[cited by applicant]
US 9682923B2
· Baroni
· 2017
[cited by examiner]
US 20090317388A1
· Burkly et al.
· 2009
[cited by applicant]
US 20100190162A1
· Rotter et al.
· 2010
[cited by applicant]
US 20140255302A1
· Poulton et al.
· 2014
[cited by applicant]
US 20160096885A1
· Shih et al.
· 2016
[cited by applicant]
US 20230272098A1
· Kruidenier et al.
· 2023
[cited by applicant]
US 20230304095A1
· McGovern et al.
· 2023
[cited by applicant]
US 20240309104A1
· Luo et al.
· 2024
[cited by applicant]
CN 101198624A
· 2008
[cited by applicant]
CN 101903402A
· 2010
[cited by applicant]
JP 2009526756A
· 2009
[cited by applicant]
WO WO2006122079A1
· 2006
[cited by applicant]
WO WO2007133816A2
· 2007
[cited by applicant]
WO WO2009064854A2
· 2009
[cited by applicant]
WO WO2014160883A1
· 2014
[cited by applicant]
WO WO2014186665A2
· 2014
[cited by applicant]
Shih et al., Reversal of Murine Colitis and Fibrosis by Neutralizing TL1A Antibody: Potential Novel Therapy to Alter Natural History of Crohn's Disease, Gastroenterology, vol. 142, Issue 5, Supplement 1, p. S-84, Abstra…
[cited by examiner]
Kidd et al., CTGF, intestinal stellate cells and carcinoid fibrogenesis, World J. Gastroenterol. 13(39):5208-5216, Oct. 21, 2007.
[cited by examiner]
Guo-Qiu et al., The Level of Connective Tissue Growth Factor in Sera of Patients with Hepatitis B Virus Strongly Correlates with Stage of Hepatic Fibrosis, Viral Immunol. 23(1):71-78, 2010.
[cited by examiner]
Vozenin-Brotons et al., Fibrogenic signals in patients with radiation enteritis are associated with increased connective tissue growth factor expression, Int. J. Rad. Oncol. 56(20):561-572, Jun. 1, 2003.
[cited by examiner]
Dendooven et al., Connective tissue growth factor (CTGF/CCN2) Elisa: a novel tool for monitoring fibrosis, Biomarkers, 16(4):289-301, May 2011.
[cited by examiner]
Leask et al., Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease?, J. Cell. Commun. Signal. 3:89-94, 2009.
[cited by examiner]
Di Mola et al., Differential Expression of Connective Tissue Growth Factor in Inflammatory Bowel Disease, Digestion, 69:245-253, 2004.
[cited by examiner]
Selet Science, FlowCytomix Announces New Multiplexing Kits for Assessing T Helper Cell Differentiation, Retrieved online from: <URL:https://www.selectscience.net/article/flowcytomix-announces-new-multiplexing-kits-for-a…
[cited by examiner]
Mifflin et al., Intestinal myofibroblasts: targets for stem cell therapy, J. Physiol. Gastrointest. Liver Physiol. 300(5):G684-G696, 2011.
[cited by examiner]
Welz et al., Fibrosis and Inflammation in Inflammatory Bowel Disease—More Than 2 Sides of the Same Coin?, Gatroenterol. 164(1):19-21, Jan. 2023.
[cited by examiner]
Adler et al.: Anti-tumor necrosis factor [alpha] prevents bowel fibrosis assessed by messenger RNA, histology, and magnetization transfer MRI in rats with Crohn's disease. Inflamm Bowel Dis 19(4):683-690 (2013).
[cited by applicant]
Andoh et al.: Mucosal cytokine network in inflammatory bowel disease. World J Gastroenterol. 14(33):5154-5161 (2008).
[cited by applicant]
Bamias et al.: Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. Journal of Immunology 171(9):4868-4874 (2003).
[cited by applicant]
Bamias et al.: Role of TL1A and its Receptor DR3 in Two Models of Chronic Murine Ileitis, PNAS, 103(22):8441-8446, 2006.
[cited by applicant]
Barrett et al.: Constitutive TL1A Expression under Colitogenic Condition Modulates the Severity and Location of Gut Mucosal Inflammation and Induces Fibrostenosis, American Journal of Pathology, 180(2):636-649 (2012).
[cited by applicant]
Bioque et al.: Further evidence for a genetic association of interleukin-1 receptor antagonist and ulcerative colitis in the Northern and Mediterranean population. Gastroenterology 108:a783 (1995) Abstract only.
[cited by applicant]
Brand et al.: IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am J Physiol Gastrointest Liver Physiol. 290:G827-838 (2006).
[cited by applicant]
Bull et al.: The death receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. J.Exp.Med., 205(11):2457-2464, 2008.
[cited by applicant]
Burke et al.: Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease. Inflammatory Bowel Diseases. 14(9):1197-1204 (2008).
[cited by applicant]
Camoglio et al.: Altered expression of interfero-gamma and interleukin-4 in inflammatory bowel disease; Inflamm Bowel Dis., 4(4): 285-290; Abstract only (1998).
[cited by applicant]
Chen et al.: Discordant protein and mRNA expression in lung adenocarcinomas. Mol. Cell. Proteomics, 4:304-313, 2002.
[cited by applicant]
Chen et al.: Screening for genes associated with cardiac fibrosis induced by aldosterone. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi Journal of Cellular and Molecular Immuno 28(4):350-353 (2012) (English Abstract & Translation…
[cited by applicant]
Dambacher et al.: Interleukin 31 mediates MAP kinase and STAT⅓ activation in intestinal epithelial cells and its expression is upregulated in inflammatory bowel disease. Gut. 56:1257-1265 (2007).
[cited by applicant]
Duerr et al.: Association between ulcerative colitis and a polymorphism in intron 2 of the interleukin-2 receptor antagonist gene. Gastroenterology Abstract Only 108:a812 (1995).
[cited by applicant]
European Patent Application No. EP14773989.0 Strawman Limited Opposition Against EP2978440 dated Jul. 1, 2020.
[cited by applicant]
Fessler et al.: A genomic and proteomic analysis of activation of the human neutrophil by Lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase. The Journal of Biological Chemistry, 277(35):31291-…
[cited by applicant]
Fitzpatrick, LR, Novel Pharmacological Approaches for Inflammatory Bowl Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis, International Journal of Inflammation, vol. 2012, pp. 1-8.
[cited by applicant]
Gologan et al.: Inflammatory gene expression profiles in Crohn's disease and ulcerative colitis: A comparative analysis using a reverse transcriptase multiplex ligation-dependent probe amplification protocol. Journal of…
[cited by applicant]
Halme et al.: Family and twin studies in inflammatory bowel disease. World J Gastroenterol. 12(23):3668-3672 (2006).
[cited by applicant]
Hsu et al.: The tale of TL1A in inflammation. Mucosal Immunol 4(4):368-370, 2011.
[cited by applicant]
Koga et al.: Transanal Delivery of Angiotensin Converting Enzyme Inhibitor Prevents Colonic Fibrosis in a Mouse Colitis Model: Development of a Unique Mode of Treatment, Surgery, 144(2):259-268, 2008.
[cited by applicant]
Mansfield et al.: Novel genetic association between ulcerative colitis and the antiinflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 106:637-642 (1994).
[cited by applicant]
Mazzei et al.: Suppression of intestinal inflammation and inflammation-driven colon cancer in mice by dietary sphingomyelin: importance of PPAR-γ expression. J Nutr Biochem. 22(12):1160-1171 (2011) doi:10.1016/j.jnutbio…
[cited by applicant]
Meylan et al.: The TNF-family cytokine TL1A drives IL-13 dependent small intestinal inflammation. Muscosal Immunol., 4(2):172-185, 2011.
[cited by applicant]
Migone et al.: TL1A is a TNF-like Ligand for DR3 and TR6/DcR3 and Functions as a T cell Costimulator, Immunity, 16:479-492, 2002.
[cited by applicant]
Muzes et al.: Changes of the cytokine profile in inflammatory bowel diseases. World J Gastroenterol. 18(41):5848-5861 (2012).
[cited by applicant]
NCBI Gene Database. Gene ID: 133396, IL31RA interleukin 31 receptor A [
[cited by applicant]
NCBI Gene Database, Gene ID: 3458, IFNG interferon gamma [
[cited by applicant]
Ostanin et al.: T cell transfer model of chronic colitis: consents, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol. 296(2):G135-G146 (2009).
[cited by applicant]
Papadakis et al.: Dominant Role for TL1A/DR3 Pathway in IL-12 plus IL-18-Induced IFN-γ Production by Peripheral Blood and Mucosal CCR9+ T Lymphocytes. the Journal of Immunology. 174:4985-4900 (2005).
[cited by applicant]
Papadakis et al.: IL1A synergizes with IL-12 and IL-18 to enhance IFN-y production in human T cells and NK cells, The Journal of Immunology, 172:7002-7007, 2004.
[cited by applicant]
Parente et al.: Bowel Ultrasound in Assessment of Crohn's Disease and Detection of Related Small Bowel Strictures: A Prospective Comparative Study Versus X Ray and Intraoperative Findings, Gut, 50: 490-495, 2002.
[cited by applicant]
PCT/US2014/032054 International Search Report and Written Opinion dated Aug. 5, 2014, 14 pages.
[cited by applicant]
Pinchuk et al.: Human Colonic Myofibroblast Promote Expansion of CD4+ CD25high Foxp3+ Regulatory T Cells, Gastroenterology, 140(7):2019-2030, pp. 1-19, and p. 8, 2011.
[cited by applicant]
Prometheus Biosciences, Inc. Form S-1 Registration Statement as filed with the Securities and Exchange Commission on Feb. 19, 2021 (246 pages).
[cited by applicant]
Rieder et al.: Intestinal Fibrosis in Inflammatory Bowel Disease—Current Knowledge and Future Perspectives, J.Crohns Colitis, 2:279-290, 2008.
[cited by applicant]
Rieder et al.: Managing Intestinal Fibrosis in Patients With Inflammatory Bowel Disease. Gastroenterol Hepatol (NY). 14(2):120-122 (2018).
[cited by applicant]
Shih et al.: Constitutive TL1A (TNFSF15) Expression on Lymphoid or Myeloid Cells Leads to Mild Intestinal Inflammation and Fibrosis, PLOS One, 6(1), pp. 1-16, 2011.
[cited by applicant]
Shih et al.: Inhibition of a novel fibrogenic factor TI 1a reverses established colonic fibrosis. Mucosal Immunol., 7(6):1492-1503, 2014.
[cited by applicant]
Spinelli et al.: Intestinal Fibrosis in Crohn's Disease: Medical Treatment or Surgery?, Current Drug Targets, 11(2):242-248, 2010.
[cited by applicant]
Strober et at, Proinflammatoly Cytokines in Pathogenesis of Inflammatory Bowel Diseases, Gastroenterology, 140(6):1756-1767, 2011.
[cited by applicant]
Takedatsu et al.: TL1A (TNFSF15) Regulates the Development of Chronic Colitis by Modulating both T helper (TH) 1 and TH17 Activation; Gastroenterology; HHS Public Access; 135(2): 552-567 (2008).
[cited by applicant]
Tountas et al.: Genetic association between allele 2 of IL-1 receptor antagonist (IL-1 ra) and ulcerative colitis in Los Angeles based hispanic population. Abstract XP000673112 only. Gastroenterology 108:806-813 (1995).
[cited by applicant]
Tountas et al.: Heterogenous association between allele 2 of IL-2 receptor antagonist (ILC4371 RA) and ulcerative colitis in Jewish and non-Jewish populations. Abstract XP000673114 only. J. Investigative Medicine 44(1) …
[cited by applicant]
UniprotKB Database, Q8NI17 (IL31R_Human), Retrieved online Sep. 5, 2019. Retrieved from <url <a= href=>https://www.uniprot.org/uniprot/Q8NI17. Jul. 31, 2019.</url>.
[cited by applicant]
U.S. Appl. No. 14/779,893 Final Office Action dated Apr. 26, 2019.
[cited by applicant]
U.S. Appl. No. 14/779,893 Office Action dated Jul. 5, 2017.
[cited by applicant]
U.S. Appl. No. 14/779,893 Office Action dated Mar. 21, 2018.
[cited by applicant]
U.S. Appl. No. 14/779,893 Office Action dated Sep. 12, 2019.
[cited by applicant]
U.S. Appl. No. 14/779,893 Office Action dated Sep. 7, 2018.
[cited by applicant]
U.S. Appl. No. 16/388,101 Restriction Requirement dated Jul. 10, 2020.
[cited by applicant]
U.S. Appl. No. 16/798,030 Office Action dated Oct. 29, 2021.
[cited by applicant]
Yagi et al.: Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts. International Journal of Molecular Medicine, 19:941-946, 2007.
[cited by applicant]
Zhang et al.: Structures and biological functions of IL-31 and IL-31 receptors. Cytokine Growth Factor. 19(5-6):347-356 (2008).
[cited by applicant]
Zheng et al.: 2013 AGA Abstracts 2013 Gastroenterol. 144(5): Supplement 1: p. S-132; Abstract 735 (2013).
[cited by applicant]
Zheng et al.: Dynamic expression and significance of IL-31 in the process of pulmonary fibrosis in experimental mice. Shadong Medical Journal. 49(13):26-27 (2009).
[cited by applicant]
Zheng et al.: Sustained TL1A (TNFSF15) Expression on both Lymphoid and Myeloid Cells Leads to Mild Spontaneous Intestinal Inflammation and Fibrosis. European Journal of Microbiology and Immunology 3(1):11-20 (2013).
[cited by applicant]
Cornelissen, Christian. et al. Signaling by IL-31 and functional consequences. European journal of cell biology 91(6-7):552-566 (2012).
[cited by applicant]
EP20190199149.6 Notice of Opposition, Office Action dated Jun. 7, 2024.
[cited by applicant]
Flier, Sarah N. et al. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. The Journal of biological chemistry 285(26):20202-20212 (2010).
[cited by applicant]
Gonsky, R. et al. DOP29 Elevation of a novel blood-based gene signature in a severe Crohn's disease (CD) subtype preceding surgery defines and predicts a post-surgical decrease in pro-inflammatory pathway activation. Jo…
[cited by applicant]
Speca, Silvia. et al. Cellular and molecular mechanisms of intestinal fibrosis. World journal of gastroenterology 18(28):3635-3661 (2012).
[cited by applicant]
Zhang, Xiaolan. et al. Tu1650 Constitutive TL1A Expression Modulates Colonic Fibrosis on TNBS-Induced Colitis in Mice. Gastroenterology 144(5):S-814 (2013).
[cited by applicant]
Zheng, Libo. et al. Sustained TL1A (TNFSF15) Expression on both Lymphoid and Myeloid Cells Leads to Mild Spontaneous Intestinal Inflammation and Fibrosis (along with Evidence of publication date). European Journal of Mi…
[cited by applicant]
Anonymous: EP4285988 Third Party Observation dated Nov. 20, 2024 (6 pages).
[cited by applicant]
Arai et al.: Interleukin-31 Receptor A Expression in the Dorsal Root Ganglion of Mice with Atopic Dermatitis. International Journal of Molecular Sciences. 24:1047 pp. 1-16 (2023).
[cited by applicant]
Co-pending U.S. Appl. No. 18/557,551, inventors Potdar; Alka et al., filed Oct. 26, 2023.
[cited by applicant]
Co-pending U.S. Appl. No. 18/645,261, inventors Watkins; Jeffry D. et al., filed Apr. 24, 2024.
[cited by applicant]
Co-pending U.S. Appl. No. 18/649,944, inventors Stephan; R. Targan et al., filed Apr. 29, 2024.
[cited by applicant]
Mori, Toshifumi. et al. Role and interaction of connective tissue growth factor with transforming growth factor-β in persistent fibrosis: A mouse fibrosis model. Journal of cellular physiology 181(1):153-159 (1999).
[cited by applicant]
Roestenberg, Peggy. et al. Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. American Journal of Physiology—Renal Physi…
[cited by applicant]
Yokoi, Hideki. et al. Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis. American Journal of Physiology—Renal Physiology 282(5):F933-F942 (2002).
[cited by applicant]